Rare Medical News
Advertisement
Spotlight On
CANDLE syndrome
"CANDLE" stands for chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature. The most common symptoms are fevers, fat loss, and skin lesions
Prevalence
1-9 / 100 000
Ultra-rare
US Estimated
Ultra-rare
Europe Estimated
Age of Onset
Infancy
ICD-10
M04.8
D89.8
Inheritance Pattern
Autosomal dominant
Autosomal recessive
Mitochondrial/Multigenic
X-linked dominant
X-linked recessive
Rare View
CANDLE syndrome is a proteasome-associated autoinflammatory interferonopathy (PRAAS) presenting in infancy with recurrent fevers, neutrophilic dermatosis-like skin lesions, progressive lipodystrophy, and systemic inflammation. It is linked to pathogenic variants in proteasome-related genes (e.g., PSMB8, others) and is characterized by chronic inflammatory burden and growth failure. Diagnosis is clinical plus inflammatory labs/biopsy patterns and is confirmed by molecular testing; recognition matters because JAK inhibition can significantly improve disease control.
5 Facts you should know
FACT
CANDLE Syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) is an autoinflammatory disorder characterized by early-onset recurrent fevers, skin lesions, lipodystrophy, and systemic inflammation
FACT
It typically begins in early childhood, with symptoms including persistent fevers, joint stiffness, skin rashes, and progressive loss of subcutaneous fat, leading to a distinctive facial appearance and body shape
FACT
CANDLE Syndrome is caused by mutations in genes involved in the regulation of type I interferon signaling, contributing to the activation of the immune system and chronic inflammation
FACT
Diagnosis involves clinical evaluation, skin biopsies to identify specific histopathological changes, and genetic testing to confirm mutations related to interferonopathies
FACT
5
Treatment aims to manage symptoms and reduce inflammation using corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents targeting the overactive immune response
Interest over time
Google searches
Common signs & symptoms
Recurrent or persistent fevers starting early in life
Painful violaceous plaques/nodules; neutrophilic dermatosis-like eruptions
Progressive lipodystrophy (partial/generalized), failure to thrive
Arthralgia/arthritis; myositis features in some
Hepatosplenomegaly/lymphadenopathy may occur
Chronic inflammation labs (CRP/ESR elevated); interferon signature in many cases
Complications from chronic inflammation (growth delay, organ involvement)
Current treatments
Glucocorticoids may help short-term but toxicity limits long-term use
Conventional biologics (IL-1/TNF/IL-6 blockade) may be incomplete/temporary in many reports
JAK inhibitors (e.g., baricitinib) have shown meaningful clinical benefit in published experience and ongoing research
Specialist-directed multidisciplinary care: infection surveillance, metabolic/nutritional support, growth monitoring
Pharma tie-ins (possible): Eli Lilly (baricitinib), other JAK inhibitor manufacturers (class effect; off-label in many regions)
References:
- Boyadzhiev M, et al. Disease course and treatment effects of a JAK inhibitor in CANDLE (and related interferonopathies). 2019.
- Gedik KC, et al. Baricitinib exposure–response and disease flares in CANDLE/PRAAS. Ann Rheum Dis. 2024.
- McDermott A, et al. Proteasome-associated autoinflammatory syndrome / CANDLE discussion incl. JAK inhibitor rationale. 2013.